Richard Kuntz joins Tengion's board
This article was originally published in Clinica
Regenerative medicine specialist Tengion has appointed Richard Kuntz to its board of directors. Dr Kuntz is currently Medtronic's senior vice-president and chief scientific, clinical and regulatory officer. Before joining Medtronic in 2005, he was founder and chief scientific officer of the Harvard Clinical Research Institute, a contract research organisation based at the university. Dr Kuntz has directed over 100 multicentre clinical trials and has authored more than 200 scientific papers, and has experience in developing both pharmaceuticals and medical devices. East Norriton, Pennsylvania-based Tengion's technology is designed to regenerate organs and tissues from patients' own cells. Its most advanced product is the Neo-Bladder Augment, which has completed two Phase II trials in patients with neurogenic bladder (when the nerves controlling bladder function do not work properly).